A 2019 systematic overview of the randomized controlled trial analyzing the efficiency of intravenous ketamine for pain reduction in Continual refractory discomfort concluded that ketamine presents sizeable limited-phrase analgesic gain in these patients, having said that bigger, multicenter reports with for a longer period observe-ups were being